8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 11, 2026·SEC
Ironwood Pharmaceuticals, Inc.(IRWD)Earnings, Financials & Key Ratios
IRWD•NASDAQ
23.6× P/E·Price updated Jun 19, 2026
AboutIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Show more
- Revenue$296M-15.7%
- EBITDA$121M+26.8%
- Net Income$24M+2629.2%
- EPS (Diluted)0.15+2627.3%
- Gross Margin100%+2.2%
- EBITDA Margin40.74%+50.5%
- Operating Margin40.1%+51.3%
- Net Margin8.11%+3138.7%
IRWD Key Insights
Ironwood Pharmaceuticals, Inc. (IRWD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 42.9% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Profits declining 25.7% over 5 years
- ✗Sales declining 5.3% over 5 years
- ✗Shares diluted 11.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IRWD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IRWD Price & Volume
Ironwood Pharmaceuticals, Inc. (IRWD) stock price & volume — 10-year historical chart
Loading chart...
IRWD Growth Metrics
Ironwood Pharmaceuticals, Inc. (IRWD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.07%
5 Years-5.33%
3 Years-10.32%
TTM13.8%
Profit CAGR
10 Years-
5 Years-25.72%
3 Years-48.42%
TTM415.9%
EPS CAGR
10 Years-
5 Years-25.65%
3 Years-46.14%
TTM400.86%
Return on Capital
10 Years-1.74%
5 Years-1.12%
3 Years-20.42%
Last Year50.89%
IRWD Recent Earnings
Ironwood Pharmaceuticals, Inc. (IRWD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.24+242.9%
$0.07
Rev
$107M+15.6%
$92M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.01-150.0%
$0.02
Rev
$48M-6.3%
$51M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.24+166.7%
$0.09
Rev
$122M+139.6%
$51M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.14+800.0%
$0.02
Rev
$85M+9.5%
$78M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.24vs $0.07+242.9% | $107Mvs $92M+15.6% |
| Q1 2026 | Feb 25, 2026 | $0.01vs $0.02-150.0% | $48Mvs $51M-6.3% |
| Q4 2025 | Nov 10, 2025 | $0.24vs $0.09+166.7% | $122Mvs $51M+139.6% |
| Q3 2025 | Aug 7, 2025 | $0.14vs $0.02+800.0% | $85Mvs $78M+9.5% |
Based on last 12 quarters of dataView full earnings history →
IRWD Peer Comparison
Ironwood Pharmaceuticals, Inc. (IRWD) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PTGX | 7.26B | 112.86 | -55.05 | -89.41% | -6.48% | -17.76% | 0.02 | |
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 CPIX | 85.7M | 5.72 | -30.11 | 17.57% | -17.24% | -29.12% | 0.41 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 SHPH | 1.74M | 3.46 | -0.05 | -408.33% | 0.10 | |||
 VNDA | 342.83M | 5.80 | -1.55 | 8.72% | -109.99% | -61.41% | 0.04 | |
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare IRWD vs Peers
Ironwood Pharmaceuticals, Inc. (IRWD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IRWD Income Statement
Ironwood Pharmaceuticals, Inc. (IRWD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 298.28M | 346.64M | 428.41M | 389.52M | 413.75M | 410.6M | 442.74M | 351.41M | 296.15M | 361.51M |
Revenue Growth % | 8.88% | 16.21% | 23.59% | -9.08% | 6.22% | -0.76% | 7.83% | -20.63% | -15.72% | 13.8% |
Cost of Goods Sold | 19.41M | 32.75M | 135.39M | 3.14M | 70.41M | 1.42M | 6.15M | 7.55M | 0 | 1.39M |
COGS % of Revenue | 6.51% | 9.45% | 31.6% | 0.81% | 17.02% | 0.35% | 1.39% | 2.15% | - | - |
Gross Profit | 278.87M▲ 0% | 313.89M▲ 12.6% | 293.02M▼ 6.6% | 386.39M▲ 31.9% | 343.35M▼ 11.1% | 409.18M▲ 19.2% | 436.59M▲ 6.7% | 343.86M▼ 21.2% | 296.15M▼ 13.9% | 360.13M▲ 0% |
Gross Margin % | 93.49% | 90.55% | 68.4% | 99.19% | 82.98% | 99.65% | 98.61% | 97.85% | 100% | 99.62% |
Gross Profit Growth % | 2.49% | 12.56% | -6.65% | 31.86% | -11.14% | 19.17% | 6.7% | -21.24% | -13.87% | - |
Operating Expenses | 387.56M | 415.9M | 172.9M | 243.45M | 111.09M | 158.84M | 1.38B | 250.73M | 177.39M | 158.29M |
OpEx % of Revenue | 129.94% | 119.98% | 40.36% | 62.5% | 26.85% | 38.69% | 312.15% | 71.35% | 59.9% | - |
Selling, General & Admin | 233.12M | 241.29M | 0 | 140M | 0 | 115.99M | 0 | 0 | 82.26M | 70.03M |
SG&A % of Revenue | 78.16% | 69.61% | - | 35.94% | - | 28.25% | - | - | 27.77% | - |
Research & Development | 148.23M | 166.5M | 122.24M | 88.06M | 70.41M | 44.27M | 116.08M | 111.42M | 95.14M | 88.26M |
R&D % of Revenue | 49.69% | 48.03% | 28.53% | 22.61% | 17.02% | 10.78% | 26.22% | 31.71% | 32.12% | - |
Other Operating Expenses | 6.21M | 8.11M | 50.66M | 15.38M | 40.68M | -1.42M | 1.27B | 139.31M | 0 | 0 |
Operating Income | -77.39M▲ 0% | -238.89M▼ 208.7% | 120.12M▲ 150.3% | 142.94M▲ 19.0% | 232.26M▲ 62.5% | 250.34M▲ 7.8% | -945.43M▼ 477.7% | 93.12M▲ 109.8% | 118.76M▲ 27.5% | 201.84M▲ 0% |
Operating Margin % | -25.94% | -68.92% | 28.04% | 36.7% | 56.13% | 60.97% | -213.54% | 26.5% | 40.1% | 55.83% |
Operating Income Growth % | -49.19% | -208.71% | 150.28% | 18.99% | 62.49% | 7.78% | -477.66% | 109.85% | 27.53% | - |
EBITDA | -62.77M | -226.92M | 125.7M | 146.5M | 233.78M | 251.75M | -943.86M | 95.14M | 120.64M | 203.69M |
EBITDA Margin % | -21.04% | -65.46% | 29.34% | 37.61% | 56.5% | 61.31% | -213.19% | 27.07% | 40.74% | 56.34% |
EBITDA Growth % | -54.56% | -261.53% | 155.39% | 16.55% | 59.57% | 7.69% | -474.91% | 110.08% | 26.81% | 270.52% |
D&A (Non-Cash Add-back) | 14.62M | 11.97M | 5.58M | 3.56M | 1.52M | 1.42M | 1.57M | 2.01M | 1.88M | 1.84M |
EBIT | -18.55M | -156.42M | 122.97M | 138.34M | 232.22M | 260.02M | 195.84M | 95.72M | 102.77M | 203.63M |
Net Interest Income | -34.26M | -34.73M | -33.74M | -27.97M | -30.42M | 1.9M | -2.66M | -28.57M | -28.67M | -28.91M |
Interest Income | 2.11M | 2.99M | 2.86M | 1.5M | 726K | 9.5M | 18.97M | 4.47M | 4.08M | 4.91M |
Interest Expense | 36.37M | 37.72M | 36.6M | 29.48M | 31.15M | 7.6M | 21.63M | 33.03M | 32.75M | 33.82M |
Other Income/Expense | -71.16M | -43.48M | -61.18M | -34.08M | -31.6M | 2.08M | -2.64M | -27.93M | -48.73M | -30.37M |
Pretax Income | -116.94M▲ 0% | -282.37M▼ 141.5% | 58.94M▲ 120.9% | 108.86M▲ 84.7% | 200.66M▲ 84.3% | 252.42M▲ 25.8% | -948.07M▼ 475.6% | 65.2M▲ 106.9% | 70.03M▲ 7.4% | 171.47M▲ 0% |
Pretax Margin % | -39.2% | -81.46% | 13.76% | 27.95% | 48.5% | 61.48% | -214.14% | 18.55% | 23.64% | 47.43% |
Income Tax | 34.26M | -5.75M | 0 | 2.69M | -327.79M | 77.36M | 83.49M | 64.32M | 46.01M | 69.29M |
Effective Tax Rate % | -29.3% | 2.04% | 0% | 2.47% | -163.36% | 30.65% | -8.81% | 98.65% | 65.7% | 40.41% |
Net Income | -116.94M▲ 0% | -282.37M▼ 141.5% | 21.5M▲ 107.6% | 106.18M▲ 393.7% | 528.45M▲ 397.7% | 175.06M▼ 66.9% | -1B▼ 672.5% | 880K▲ 100.1% | 24.02M▲ 2629.2% | 102.18M▲ 0% |
Net Margin % | -39.2% | -81.46% | 5.02% | 27.26% | 127.72% | 42.64% | -226.37% | 0.25% | 8.11% | 28.26% |
Net Income Growth % | -43.12% | -141.47% | 107.62% | 393.73% | 397.71% | -66.87% | -672.5% | 100.09% | 2629.2% | 415.9% |
Net Income (Continuing) | -54.91M | -194.15M | 58.94M | 106.18M | 528.45M | 175.06M | -1.03B | 880K | 24.02M | 102.18M |
Discontinued Operations | 0 | 0 | -37.44M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.78▲ 0% | -1.85▼ 137.2% | -0.10▲ 94.7% | 0.66▲ 772.1% | 3.21▲ 386.4% | 0.96▼ 70.1% | -6.45▼ 771.9% | 0.01▲ 100.1% | 0.15▲ 2627.3% | 0.61▲ 0% |
EPS Growth % | -39.29% | -137.18% | 94.69% | 772.1% | 386.36% | -70.09% | -771.88% | 100.09% | - | 400.86% |
EPS (Basic) | -0.79 | -1.85 | -0.10 | 0.67 | 3.26 | 1.13 | -6.45 | 0.01 | 0.15 | - |
Diluted Shares Outstanding | 148.99M | 152.63M | 156.02M | 160.66M | 164.42M | 186.31M | 155.44M | 160.08M | 177.76M | 166.69M |
Basic Shares Outstanding | 148.42M | 152.63M | 156.02M | 159.43M | 162.25M | 154.37M | 155.44M | 159.08M | 162.22M | 163.45M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IRWD Balance Sheet
Ironwood Pharmaceuticals, Inc. (IRWD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 311.6M | 266.44M | 306.85M | 495.84M | 745.23M | 780.63M | 233.29M | 182.37M | 274.18M | 332.29M |
Cash & Short-Term Investments | 221.42M | 173.17M | 177.02M | 364.3M | 620.13M | 656.2M | 92.15M | 88.56M | 215.46M | 220.47M |
Cash Only | 125.74M | 173.17M | 177.02M | 364.3M | 620.13M | 656.2M | 92.15M | 88.56M | 215.46M | 220.47M |
Short-Term Investments | 95.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 82.16M | 80.95M | 117.25M | 122.35M | 114.04M | 115.46M | 129.12M | 81.89M | 46.74M | 105.84M |
Days Sales Outstanding | 100.54 | 85.24 | 99.89 | 114.65 | 100.6 | 102.64 | 106.45 | 85.05 | 57.61 | 90.65 |
Inventory | 735K | 0 | 648K | 0 | 0 | 1.25M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 13.82 | - | 1.75 | - | - | 321.76 | - | - | - | - |
Other Current Assets | 0 | 2.1M | 1.25M | 9.19M | 2.37M | 0 | 0 | 11.92M | 11.98M | 5.98M |
Total Non-Current Assets | 294.08M | 65.61M | 95.9M | 63.4M | 381.7M | 319.89M | 237.78M | 168.54M | 122.72M | 102.27M |
Property, Plant & Equipment | 17.27M | 17.27M | 30.17M | 25.5M | 22.93M | 20.31M | 18.17M | 15.52M | 12.75M | 12.06M |
Fixed Asset Turnover | 17.27x | 20.07x | 14.20x | 15.27x | 18.05x | 20.22x | 24.36x | 22.64x | 23.23x | 27.61x |
Goodwill | 785K | 785K | 785K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 159.91M | 0 | 0 | 0 | 0 | 0 | 3.68M | 2.86M | 2.04M | 1.84M |
Long-Term Investments | 115.24M | 47.45M | 0 | 36.95M | 0 | 15.07M | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 116.11M | 47.56M | 64.94M | 943K | 358.78M | 847K | 3.61M | 5.92M | 4.5M | 4.14M |
Total Assets | 605.67M▲ 0% | 332.05M▼ 45.2% | 402.75M▲ 21.3% | 559.24M▲ 38.9% | 1.13B▲ 101.5% | 1.1B▼ 2.3% | 471.07M▼ 57.2% | 350.91M▼ 25.5% | 396.9M▲ 13.1% | 434.57M▲ 0% |
Asset Turnover | 0.49x | 1.04x | 1.06x | 0.70x | 0.37x | 0.37x | 0.94x | 1.00x | 0.75x | 0.92x |
Asset Growth % | -14.67% | -45.18% | 21.29% | 38.86% | 101.51% | -2.34% | -57.2% | -25.51% | 13.11% | 34.28% |
Total Current Liabilities | 66.03M | 119.52M | 40.93M | 32.17M | 161.7M | 25.52M | 276.1M | 38.85M | 242.22M | 236.31M |
Accounts Payable | 15.96M | 14.89M | 5.49M | 661K | 935K | 483K | 7.83M | 2.13M | 2.9M | 3.24M |
Days Payables Outstanding | 300.15 | 165.96 | 14.79 | 76.93 | 4.85 | 124.33 | 464.86 | 102.8 | - | 601.99 |
Short-Term Debt | 4.08M | 47.55M | 0 | 3.13M | 116.86M | 0 | 199.56M | 0 | 202.93M | 203.12M |
Deferred Revenue (Current) | 195K | 252K | 875K | 0 | 0 | 0 | 2.62M | 2.03M | 0 | 3.5M |
Other Current Liabilities | 23.23M | 42M | 14.89M | 14.97M | 7.49M | 15.88M | 26.13M | 4.98M | 35.46M | 18.04M |
Current Ratio | 4.72x | 2.23x | 7.50x | 15.41x | 4.61x | 30.58x | 0.84x | 4.69x | 1.13x | 1.41x |
Quick Ratio | 4.71x | 2.23x | 7.48x | 15.41x | 4.61x | 30.53x | 0.84x | 4.69x | 1.13x | 1.41x |
Cash Conversion Cycle | -185.79 | - | 86.85 | - | - | 300.07 | - | - | - | -511.34 |
Total Non-Current Liabilities | 529.8M | 408.9M | 455.07M | 464.43M | 359.32M | 422.62M | 541.27M | 613.4M | 416.52M | 415.4M |
Long-Term Debt | 396.09M | 366.14M | 407.99M | 430.26M | 337.33M | 396.25M | 498.31M | 583.99M | 385M | 385M |
Capital Lease Obligations | 0 | 158K | 22.08M | 20.32M | 18.48M | 16.6M | 14.54M | 12.3M | 9.87M | 40.72M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 133.71M | 42.6M | 24.99M | 13.85M | 3.5M | 9.77M | 28.41M | 17.11M | 21.65M | 21.17M |
Total Liabilities | 595.83M | 528.42M | 496M | 496.6M | 521.02M | 448.14M | 817.37M | 652.24M | 658.74M | 651.71M |
Total Debt | 400.17M | 413.92M | 431.22M | 453.7M | 475.8M | 415.92M | 715.54M | 599.48M | 597.8M | 597.36M |
Net Debt | 274.43M | 240.75M | 254.2M | 89.4M | -144.33M | -240.29M | 623.38M | 510.92M | 382.35M | 376.88M |
Debt / Equity | 40.63x | - | - | 7.24x | 0.79x | 0.64x | - | - | - | -2.75x |
Debt / EBITDA | - | - | 3.43x | 3.10x | 2.04x | 1.65x | - | 6.30x | 4.96x | 2.93x |
Net Debt / EBITDA | - | - | 2.02x | 0.61x | -0.62x | -0.95x | - | 5.37x | 3.17x | 1.85x |
Interest Coverage | -0.51x | -4.15x | 3.36x | 4.69x | 7.45x | 34.22x | 9.05x | 2.90x | 3.14x | 6.02x |
Total Equity | 9.85M▲ 0% | -196.37M▼ 2094.0% | -93.25M▲ 52.5% | 62.64M▲ 167.2% | 605.91M▲ 867.3% | 652.38M▲ 7.7% | -346.3M▼ 153.1% | -301.33M▲ 13.0% | -261.83M▲ 13.1% | -217.14M▲ 0% |
Equity Growth % | -85.24% | -2094.02% | 52.51% | 167.17% | 867.29% | 7.67% | -153.08% | 12.98% | 13.11% | 67.47% |
Book Value per Share | 0.07 | -1.29 | -0.60 | 0.39 | 3.69 | 3.50 | -2.23 | -1.88 | -1.47 | -1.30 |
Total Shareholders' Equity | 9.85M | -196.37M | -93.25M | 62.64M | 605.91M | 652.38M | -346.3M | -301.33M | -261.83M | -217.14M |
Common Stock | 151K | 154K | 158K | 161K | 162K | 154K | 156K | 160K | 163K | 165K |
Retained Earnings | -1.31B | -1.59B | -1.57B | -1.47B | -937.61M | -696.38M | -1.7B | -1.7B | -1.67B | -1.63B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -79K | 0 | -10.08M | 0 | 0 | 0 | -3.03M | 923K | -1.06M | -795K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IRWD Cash Flow Statement
Ironwood Pharmaceuticals, Inc. (IRWD) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -99.56M | -70.88M | 10.72M | 168.84M | 261.89M | 273.76M | 183.43M | 103.55M | 127.04M | 112.21M |
Operating CF Margin % | -33.38% | -20.45% | 2.5% | 43.34% | 63.3% | 66.67% | 41.43% | 29.47% | 42.9% | - |
Operating CF Growth % | -291.47% | 28.81% | 115.13% | 1474.23% | 55.12% | 4.53% | -33% | -43.55% | 22.69% | 552.18% |
Net Income | -116.94M | -282.37M | 21.5M | 106.18M | 528.45M | 175.06M | -1B | 880K | 24.02M | 102.18M |
Depreciation & Amortization | 14.62M | 14.22M | 5.58M | 3.56M | 1.5M | 1.42M | 1.57M | 2.01M | 1.88M | 2.79M |
Stock-Based Compensation | 33.82M | 43.98M | 31.28M | 31.18M | 22.28M | 27.05M | 32.01M | 29.85M | 17.25M | 20.09M |
Deferred Taxes | 7.53M | 159.11M | 0 | 6.6M | -333.29M | 65.74M | 72.64M | 68.09M | 40.8M | 101.2M |
Other Non-Cash Items | -16.81M | -13.44M | 52.35M | 22.26M | 25.23M | 1.67M | 1.07B | 1.98M | 3.44M | -107.5M |
Working Capital Changes | -21.79M | 7.62M | -99.99M | -941K | 17.73M | 2.82M | 11.28M | 739K | 39.65M | -70.23M |
Change in Receivables | -17.3M | 1.21M | -68.89M | 4.09M | 7.71M | 7.99M | 924K | 47.24M | 35.15M | -66.07M |
Change in Inventory | 346K | -806K | 0 | 648K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -6.84M | 8.06M | -32.7M | -7.52M | -2.64M | -8.12M | 12.38M | -20.21M | 6.2M | -8.35M |
Cash from Investing | 151.46M | 88.87M | -11.14M | -1.84M | -265K | -136K | -1.03B | -142K | -34K | -3K |
Capital Expenditures | -4.21M | -8.62M | -7.19M | -1.84M | -265K | -136K | -273K | -142K | -34K | -7K |
CapEx % of Revenue | 1.41% | 2.49% | 1.68% | 0.47% | 0.06% | 0.03% | 0.06% | 0.04% | 0.01% | 0% |
Acquisitions | 135K | 1.56M | 0 | 0 | 0 | 0 | -1.03B | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 135K | 1.56M | -3.96M | 0 | 0 | 0 | 0 | 0 | 0 | 4K |
Cash from Financing | 19.84M | 30.07M | -1.19M | 18.55M | -4.55M | -237.55M | 277.16M | -106.97M | 216K | 210K |
Debt Issued (Net) | 8.76M | -1.82M | 19.43M | 0 | 0 | -120.7M | 300M | -115M | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 0 | 18.55M | -24.13M | -126.39M | 6.36M | 11.01M | 216K | 210K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | -24.13M | -126.39M | 0 | 0 | 0 | 0 |
Other Financing | 11.08M | 31.9M | -20.61M | 0 | 19.58M | 9.54M | -29.2M | -2.98M | 0 | 0 |
Net Change in Cash | 71.73M▲ 0% | 48.06M▼ 33.0% | -1.6M▼ 103.3% | 185.54M▲ 11667.3% | 257.08M▲ 38.6% | 36.07M▼ 86.0% | -565.78M▼ 1668.4% | -3.6M▲ 99.4% | 126.9M▲ 3629.8% | 111.99M▲ 0% |
Free Cash Flow | -103.77M▲ 0% | -79.5M▲ 23.4% | 3.54M▲ 104.4% | 166.99M▲ 4622.7% | 261.63M▲ 56.7% | 273.63M▲ 4.6% | 183.15M▼ 33.1% | 103.41M▼ 43.5% | 127.01M▲ 22.8% | 112.21M▲ 0% |
FCF Margin % | -34.79% | -22.94% | 0.83% | 42.87% | 63.23% | 66.64% | 41.37% | 29.43% | 42.89% | 31.04% |
FCF Growth % | 19.95% | 23.39% | 104.45% | 4622.68% | 56.67% | 4.59% | -33.06% | -43.54% | 22.83% | 43.1% |
FCF per Share | -0.70 | -0.52 | 0.02 | 1.04 | 1.59 | 1.47 | 1.18 | 0.65 | 0.71 | 0.67 |
FCF Conversion (FCF/Net Income) | 0.85x | 0.25x | 0.50x | 1.59x | 0.50x | 1.56x | -0.18x | 117.67x | 5.29x | 1.10x |
Interest Paid | 0 | 0 | 17.58M | 7.22M | 7.22M | 5.75M | 13.55M | 32.56M | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 1.85M | 3.45M | 4.62M | 9.95M | 8.41M | 0 | 0 |
IRWD Key Ratios
Ironwood Pharmaceuticals, Inc. (IRWD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -305.46% | - | - | 169.5% | 158.09% | 27.83% | -654.88% | - | - | -38.88% |
Return on Invested Capital (ROIC) | -17.33% | -109.03% | 87.75% | 68.5% | 56.78% | 42.98% | -205.77% | 28.7% | 53.97% | 90.16% |
Gross Margin | 93.49% | 90.55% | 68.4% | 99.19% | 82.98% | 99.65% | 98.61% | 97.85% | 100% | 99.62% |
Net Margin | -39.2% | -81.46% | 5.02% | 27.26% | 127.72% | 42.64% | -226.37% | 0.25% | 8.11% | 28.26% |
Debt / Equity | 40.63x | - | - | 7.24x | 0.79x | 0.64x | - | - | - | -2.75x |
Interest Coverage | -0.51x | -4.15x | 3.36x | 4.69x | 7.45x | 34.22x | 9.05x | 2.90x | 3.14x | 6.02x |
FCF Conversion | 0.85x | 0.25x | 0.50x | 1.59x | 0.50x | 1.56x | -0.18x | 117.67x | 5.29x | 1.10x |
Revenue Growth | 8.88% | 16.21% | 23.59% | -9.08% | 6.22% | -0.76% | 7.83% | -20.63% | -15.72% | 13.8% |
Related:IRWD Dividend History·IRWD Revenue History·IRWD Price History·IRWD P/E History·IRWD Financial Ratios·IRWD Institutional Holders
IRWD SEC Filings & Documents
Ironwood Pharmaceuticals, Inc. (IRWD) SEC filings — annual & quarterly reports (10-K, 10-Q)
IRWD Frequently Asked Questions
Ironwood Pharmaceuticals, Inc. (IRWD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ironwood Pharmaceuticals, Inc. (IRWD) reported $361.5M in revenue for fiscal year 2025. This represents a 3355% increase from $10.5M in 2007.
Ironwood Pharmaceuticals, Inc. (IRWD) saw revenue decline by 15.7% over the past year.
Yes, Ironwood Pharmaceuticals, Inc. (IRWD) is profitable, generating $102.2M in net income for fiscal year 2025 (8.1% net margin).
Dividend & Returns
Ironwood Pharmaceuticals, Inc. (IRWD) generated $112.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.